Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An application of cystine in preparation of a medicine for reducing hepatotoxicity caused by adriamycin

A liver toxicity, doxorubicin technology, applied in the field of medicine, can solve problems such as hair loss, liver and kidney function damage

Inactive Publication Date: 2018-01-09
CHINA PHARM UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinical reports have shown that adverse reactions such as cardiotoxicity, bone marrow suppression, liver and kidney function damage, gastrointestinal reactions, and hair loss often occur in patients receiving doxorubicin chemotherapy.
There is no report that cystine can effectively reverse the hepatotoxicity of tumor chemotherapy drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An application of cystine in preparation of a medicine for reducing hepatotoxicity caused by adriamycin
  • An application of cystine in preparation of a medicine for reducing hepatotoxicity caused by adriamycin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0008] The present invention is explained in detail by the following examples, but it does not mean that the present invention is limited thereto.

[0009] Cell source and culture: human breast cancer doxorubicin-resistant cell line MCF-7 / ADR was purchased from Tianjin Institute of Hematology, Chinese Academy of Medical Sciences (Tianjin, China), and the cells were cultured at 37°C with 5% CO 2 In the environment, the culture medium is RPMI1640 medium, containing 10% fetal bovine serum (FBS), and streptomycin 100mg / L, penicillin 62.5mg / L. The cells were grown in a 10 cm culture dish, and the medium was changed once every 2-3 days, and the cells were passaged when the cells grew to 90% confluence.

[0010] Source and feeding of animals: Balb / c-nu / nu mice (female, provided by the Institute of Model Animals, Nanjing University, aged 4-6 weeks, weighing 20±2g) were used for experiments. Under the standard feeding environment (eating and drinking freely, alternation of day and nig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An application of cystine in preparation of a medicine for reducing hepatotoxicity caused by adriamycin is disclosed. Through building a human-derived breast cancer cell MCF-7 / ADR tumor-bearing mousemodel, and through dosing mice with adriamycin and cystine separately and dosing mice with the adriamycin and cystine in combination, results show that the cystine can effectively improve hepatic celllesion and necrocytosis caused by the adriamycin, and can significantly reduce contents of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum of mice affected with liver injury caused by the adriamycin. The cystine can be used in combination to reverse hepatotoxicity of the adriamycin, can improve liver functions, and can be applied as a liver protecting agent for the adriamycin that is an antitumor medicine.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a new application of cystine, that is, the application of cystine in the preparation of drugs for reducing liver toxicity caused by doxorubicin. Background technique [0002] Doxorubicin (adriamycin, ADR or doxorubicin, DOX) is the first anthraquinone antibiotic isolated from the glycolysis product of mutant Streptomyces peucetius by Italian scientists in 1969, which can inhibit RNA and DNA Synthetic, so as to produce curative effect on a variety of tumors, is a cycle non-specific drug, and has a strong killing effect on tumor cells of various growth cycles. Since the drug was used in the clinical treatment of cancer, it is considered to be an efficient and broad-spectrum anticancer drug for the treatment of solid tumors, and is widely used in the treatment of leukemia, malignant lymphoma, breast cancer, lung cancer, etc. However, clinical reports have shown that adverse reactions such as c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/198A61K31/704A61P1/16A61P35/00
Inventor 王广基阿基业冯冬
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com